^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    icosapent ethyl

    i
    Other names: AMR 101, LAX 101, ethyl eicosapentaenoate, ethyl icopenate, ethyl-EPA, icosapent ethyl, icosapentaenoic acid ethyl ester, LAX 101c, ultra-pure eicosapentaenoic acid, ultra-pure EPA, LAX101, AMR101, MND-21, EPA-E
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    Phospholipase A2 inhibitor, Caspase inhibitor, DGAT inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia (clinicaltrials.gov)
    P3, N=316, Completed, Mochida Pharmaceutical Company, Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Dec 2023 --> Jul 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    icosapent ethyl
    4ms
    Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. (PubMed, J Am Heart Assoc)
    These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • ICAM1 (Intercellular adhesion molecule 1)
    |
    icosapent ethyl
    5ms
    The sphingosine-1-phosphate receptor 1 mediates the atheroprotective effect of eicosapentaenoic acid. (PubMed, Nat Metab)
    Finally, we show that Vascepa, a prescription drug containing highly purified and stable EPA ethyl ester, exerts its cardiovascular protective effect through the 17,18-EEQ-S1PR1 pathway in male and female mice. Collectively, our findings indicate that the anti-inflammatory effect of 17,18-EEQ involves the activation of the S1PR1-Gq-Ca2+-eNOS axis in ECs, offering a potential therapeutic target against atherosclerosis.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • NOS3 (Nitric oxide synthase 3) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    |
    icosapent ethyl
    5ms
    SALVAGE: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion (clinicaltrials.gov)
    P2, N=110, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    New P2 trial
    |
    icosapent ethyl
    8ms
    IPE-PREVENTION: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk (clinicaltrials.gov)
    P4, N=70, Completed, Canadian Medical and Surgical Knowledge Translation Research Group | Active, not recruiting --> Completed
    Trial completion
    |
    CRP (C-reactive protein)
    |
    icosapent ethyl
    8ms
    ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov)
    P4, N=200, Recruiting, University of Louisville | Not yet recruiting --> Recruiting
    Enrollment open
    |
    icosapent ethyl
    9ms
    ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov)
    P4, N=200, Not yet recruiting, University of Louisville
    New P4 trial
    |
    icosapent ethyl
    11ms
    Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)
    P1/2, N=1, Terminated, National Cancer Institute (NCI) | N=18 --> 1 | Trial completion date: Jun 2026 --> Dec 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2023; Other - Poor accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • EPHA2 (EPH receptor A2) • ABCA1 (ATP Binding Cassette Subfamily A Member 1)
    |
    PGR expression
    |
    dasatinib • icosapent ethyl
    11ms
    BRAVE-EPA: Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (clinicaltrials.gov)
    P2/3, N=131, Completed, VA Office of Research and Development | Active, not recruiting --> Completed
    Trial completion
    |
    icosapent ethyl
    12ms
    EMT2: EPA for Metastasis Trial 2 (clinicaltrials.gov)
    P3, N=418, Active, not recruiting, Mark A Hull, PhD FRCP | Recruiting --> Active, not recruiting
    Enrollment closed • Surgery
    |
    icosapent ethyl
    almost2years
    IMPACT OF ICOSAPENT ETHYL ON ALZHEIMERS DISEASE BIOMARKERS IN PRECLINICAL ADULTS: BRAIN AMYLOID AND VASCULAR EFFECTS OF EIOSCAPENTAEOIC ACID (BRAVE-EPA) STUDY DESIGN AND BASELINE CHARACTERISTICS. (CTAD 2022)
    "US military Veterans are an important cohort to study in identifying mechanisms to reduce AD risk. These data support the feasibility of recruiting cognitively unimpaired Veterans into a randomized, placebo-controlled clinical trial assessing the impact of IPE on MRI, CSF, and cognitive AD biomarkers. Trial data collection is ongoing and will be completed in September 2023."
    Preclinical
    |
    icosapent ethyl
    over2years
    Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)
    P1/2, N=18, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CASP3 (Caspase 3)
    |
    PGR expression
    |
    dasatinib • icosapent ethyl
    almost3years
    Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CASP3 (Caspase 3)
    |
    PGR expression
    |
    dasatinib • icosapent ethyl
    almost3years
    OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Massachusetts General Hospital | N=36 --> 0 | Trial completion date: Sep 2023 --> Nov 2021 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2021 --> Nov 2021
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • FOXP3 (Forkhead Box P3)
    |
    icosapent ethyl
    3years
    Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, University of Leeds | Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Sep 2021
    Enrollment open • Trial initiation date • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    icosapent ethyl
    almost4years
    Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P, N=250, Not yet recruiting, University of Leeds
    New trial • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    icosapent ethyl